Bio Path Holdings Inc
NASDAQ:BPTH

Watchlist Manager
Bio Path Holdings Inc Logo
Bio Path Holdings Inc
NASDAQ:BPTH
Watchlist
Price: 0.0587 USD -2.17% Market Closed
Market Cap: 487.8k USD

BPTH's latest stock split occurred on Feb 23, 2024

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, BPTH traded at 0.362 per share. Afterward, the share price was about 5.85.

The adjusted shares began trading on Feb 23, 2024. This was BPTH's 3rd stock split, following the previous one in Jan 18, 2019.

Last Splits:
Feb 23, 2024
1-for-20
Jan 18, 2019
1-for-20
Feb 9, 2018
1-for-10
Pre-Split Price
7.24 0.362
Post-Split Price
5.85
Before
After
Last Splits:
Feb 23, 2024
1-for-20
Jan 18, 2019
1-for-20
Feb 9, 2018
1-for-10

Bio Path Holdings Inc
Stock Splits History

BPTH Stock Splits Timeline
Feb 23, 2024
Feb 23, 2024
Split 1-for-20
/0.05
Pre-Split Price
7.24 0.362
Post-Split Price
5.85
Before
After
Jan 18, 2019
Jan 18, 2019
Split 1-for-20
/0.05
Pre-Split Price
50.4 0.126
Post-Split Price
35
Before
After
Feb 9, 2018
Feb 9, 2018
Split 1-for-10
/0.1
Pre-Split Price
744 0.186
Post-Split Price
740
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.14 0.14 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.46 8.46 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Bio Path Holdings Inc
Glance View

Market Cap
487.8k USD
Industry
Biotechnology

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The company utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein. Its modified product named prexigebersen-A, is its fourth drug candidate.

BPTH Intrinsic Value
0.0676 USD
Undervaluation 13%
Intrinsic Value
Price
Back to Top